AllianceBernstein’s ANI Pharmaceuticals ANIP Stock Holding History

AllianceBernstein’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.61M	Buy	20,332 +18	+0.1%	+$1.41K	﹤0.01%	2111
2025 Q4	$1.6M	Buy	20,314 +4	+0%	+$346	﹤0.01%	2119
2025 Q3	$1.86M	Buy	20,310 +300	+1%	+$24.5K	﹤0.01%	2043
2025 Q2	$1.31M	Hold	20,010	–	–	﹤0.01%	2153
2025 Q1	$1.34M	Hold	20,010	–	–	﹤0.01%	2099
2024 Q4	$1.11M	Hold	20,010	–	–	﹤0.01%	2284
2024 Q3	$1.19M	Hold	20,010	–	–	﹤0.01%	2224
2024 Q2	$1.27M	Buy	20,010 +4,100	+26%	+$266K	﹤0.01%	2185
2024 Q1	$1.1M	Buy	15,910 +1,630	+11%	+$98.4K	﹤0.01%	2215
2023 Q4	$787K	Hold	14,280	–	–	﹤0.01%	2388
2023 Q3	$829K	Hold	14,280	–	–	﹤0.01%	2334
2023 Q2	$769K	Buy	14,280 +1,330	+10%	+$59K	﹤0.01%	2417
2023 Q1	$514K	Sell	12,950 -1,803	-12%	-$76K	﹤0.01%	2556
2022 Q4	$594K	Buy	14,753 +33	+0.2%	+$1.24K	﹤0.01%	2536
2022 Q3	$473K	Sell	14,720 -135	-0.9%	-$4.62K	﹤0.01%	2674
2022 Q2	$441K	Buy	14,855 +72	+0.5%	+$2.08K	﹤0.01%	2732
2022 Q1	$416K	Buy	14,783 +290	+2%	+$10.8K	﹤0.01%	2754
2021 Q4	$668K	Sell	14,493 -3,117	-18%	-$134K	﹤0.01%	2620
2021 Q3	$578K	Sell	17,610 -450	-2%	-$14K	﹤0.01%	2706
2021 Q2	$633K	Sell	18,060 -3,609	-17%	-$123K	﹤0.01%	2716
2021 Q1	$783K	Buy	21,669 +2,250	+12%	+$70.4K	﹤0.01%	2500
2020 Q4	$564K	Buy	19,419 +1,207	+7%	+$34.6K	﹤0.01%	2541
2020 Q3	$514K	Sell	18,212 -714	-4%	-$21.3K	﹤0.01%	2514
2020 Q2	$612K	Buy	18,926 +4,826	+34%	+$173K	﹤0.01%	2478
2020 Q1	$574K	Sell	14,100 -400	-3%	-$21.3K	﹤0.01%	2279
2019 Q4	$894K	Buy	14,500 +50	+0.3%	+$3.31K	﹤0.01%	2324
2019 Q3	$1.05M	Sell	14,450 -1,700	-11%	-$127K	﹤0.01%	2229
2019 Q2	$1.33M	Buy	16,150 +5,900	+58%	+$420K	﹤0.01%	2189
2019 Q1	$723K	Hold	10,250	–	–	﹤0.01%	2393
2018 Q4	$461K	Hold	10,250	–	–	﹤0.01%	2516
2018 Q3	$580K	Hold	10,250	–	–	﹤0.01%	2563
2018 Q2	$685K	Buy	10,250 +900	+10%	+$56.2K	﹤0.01%	2489
2018 Q1	$544K	Sell	9,350 -10,938	-54%	-$694K	﹤0.01%	2502
2017 Q4	$1.31M	Buy	20,288 +10,838	+115%	+$674K	﹤0.01%	2123
2017 Q3	$496K	Sell	9,450 -1,100	-10%	-$52.5K	﹤0.01%	2575
2017 Q2	$494K	Buy	10,550 +2,600	+33%	+$125K	﹤0.01%	2619
2017 Q1	$394K	Sell	7,950 -48,300	-86%	-$2.71M	﹤0.01%	2606
2016 Q4	$3.41M	Buy	56,250 +4,800	+9%	+$293K	﹤0.01%	1442
2016 Q3	$3.41M	Buy	51,450 +23,770	+86%	+$1.49M	﹤0.01%	1372
2016 Q2	$1.54M	Buy	27,680 +16,330	+144%	+$794K	﹤0.01%	1930
2016 Q1	$382K	Hold	11,350	–	–	﹤0.01%	2501
2015 Q4	$512K	Hold	11,350	–	–	﹤0.01%	2446
2015 Q3	$448K	Hold	11,350	–	–	﹤0.01%	2525
2015 Q2	$704K	Buy	11,350 +7,400	+187%	+$440K	﹤0.01%	2449
2015 Q1	$247K	Sell	3,950 -1,400	-26%	-$85.2K	﹤0.01%	2744
2014 Q4	$302K	Buy	5,350 +2,550	+91%	+$112K	﹤0.01%	2671
2014 Q3	$79K	Hold	2,800	–	–	﹤0.01%	3010
2014 Q2	$96K	Buy	2,800 +2,601	+1,307%	+$81.6K	﹤0.01%	3006
2014 Q1	$6K	Hold	199	–	–	﹤0.01%	3322
2013 Q4	$4K	Hold	199	–	–	﹤0.01%	3164
2013 Q3	$2K	Buy	+199	New	+$1.43K	﹤0.01%	3224

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AllianceBernstein's ANIP Position: Q1 2026 in Review

AllianceBernstein increased its ANI Pharmaceuticals (ANIP) stake by 0.09% in Q1 2026, buying an estimated $1.41K and bringing the position to 20,332 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2111.

AllianceBernstein first reported a position in ANIP in Q3 2013 and has held it in 51 quarters since. The position peaked at $3.41M in Q3 2016. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

AllianceBernstein held 20,332 shares of ANI Pharmaceuticals worth $1.61M as of Q1 2026.
AllianceBernstein bought 18 ANI Pharmaceuticals shares in Q1 2026, an estimated $1.41K.
ANI Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2111 holding.
AllianceBernstein first reported a position in ANI Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
AllianceBernstein's ANI Pharmaceuticals position peaked at $3.41M in Q3 2016.
280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.